Steven Cohen Uni Qure N.V. Transaction History

Point72 Asset Management, L.P.

$40.1 Billion
Q1 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Uni Qure N.V. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 130,075 shares of QURE stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

130,075

Previous 1,771,352 92.66%

Holding current value

$1.97 Million

Previous $31.3 Million 95.59%

% of portfolio

0.0%

Previous 0.07%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$10.6 - $18.08 $17.4 Million - $29.7 Million	-1,641,277 Reduced 92.66%	130,075 $1.38 Million
Q4 2024 Feb 14, 2025	BUY	$4.54 - $17.73 $3.61 Million - $14.1 Million	794,459 Added 81.33%	1,771,352 $31.3 Million
Q3 2024 Nov 14, 2024	BUY	$3.78 - $10.12 $2.85 Million - $7.62 Million	752,889 Added 336.11%	976,893 $4.82 Million
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $170,244 - $210,575	38,780 Added 20.94%	224,004 $1 Million
Q1 2024 May 15, 2024	SELL	$4.82 - $6.93 $3.6 Million - $5.17 Million	-746,061 Reduced 80.11%	185,224 $963,000
Q4 2023 Feb 14, 2024	BUY	$5.63 - $8.27 $5.01 Million - $7.36 Million	890,310 Added 2172.81%	931,285 $6.3 Million
Q3 2023 Nov 14, 2023	SELL	$6.71 - $11.83 $1.83 Million - $3.22 Million	-272,025 Reduced 86.91%	40,975 $274,000
Q2 2023 Aug 14, 2023	SELL	$11.12 - $22.2 $9.24 Million - $18.4 Million	-830,910 Reduced 72.64%	313,000 $3.59 Million
Q1 2023 May 15, 2023	SELL	$18.7 - $23.07 $9.89 Million - $12.2 Million	-528,920 Reduced 31.62%	1,143,910 $23 Million
Q4 2022 Feb 14, 2023	SELL	$18.12 - $27.32 $46.9 Million - $70.7 Million	-2,587,056 Reduced 60.73%	1,672,830 $37.9 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $7.47 Million - $11.2 Million	440,186 Added 11.52%	4,259,886 $79.9 Million
Q2 2022 Aug 15, 2022	BUY	$13.15 - $20.45 $7.49 Million - $11.6 Million	569,400 Added 17.52%	3,819,700 $71.2 Million
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $18.7 Million - $27.6 Million	1,284,780 Added 65.37%	3,250,300 $58.7 Million
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $22.5 Million - $40 Million	1,109,520 Added 129.62%	1,965,520 $40.8 Million
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $26.5 Million - $38.9 Million	-1,018,700 Reduced 54.34%	856,000 $27.4 Million
Q2 2021 Aug 16, 2021	SELL	$29.97 - $37.17 $1.05 Million - $1.3 Million	-35,063 Reduced 1.84%	1,874,700 $57.7 Million
Q1 2021 May 17, 2021	BUY	$29.24 - $42.03 $41.6 Million - $59.7 Million	1,421,430 Added 291.08%	1,909,763 $64.3 Million
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $15.2 Million - $21.9 Million	-431,377 Reduced 46.9%	488,333 $17.6 Million
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $6.31 Million - $8.35 Million	-175,256 Reduced 16.01%	919,710 $33.9 Million
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $49.3 Million - $74.2 Million	1,094,966 New	1,094,966 $49.3 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $22.8 Million - $42.2 Million	-570,180 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $17.4 Million - $35.1 Million	469,948 Added 468.86%	570,180 $40.9 Million
Q3 2019 Nov 15, 2019	SELL	$39.36 - $76.8 $9.67 Million - $18.9 Million	-245,768 Reduced 71.03%	100,232 $3.95 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $18.3 Million - $28.4 Million	346,000 New	346,000 $27 Million
Q1 2018 May 15, 2018	SELL	$17.1 - $26.61 $3.85 Million - $5.99 Million	-225,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$9.47 - $19.59 $2.13 Million - $4.41 Million	225,000	225,000 $4.41 Million

Others Institutions Holding QURE

# of Institutions

178

Shares Held

50.7M

Call Options Held

2.13M

Put Options Held

480K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $706M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account